^
    Back
    Association details:
    Biomarker:GNRHR expression
    Cancer:Triple Negative Breast Cancer
    Drug:triptorelin (GnRH agonist) +
    AEZS 136 (PI3K inhibitor, ERK2 inhibitor, ERK1 inhibitor) +
    AEZS-134 (ERK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Target Oncol
    Title:

    Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC)

    Published date:
    10/09/2014
    Excerpt:
    GnRH receptor expression of TNBC cell lines MDA-MB-231 and HCC1806 was investigated...Cells were treated with triptorelin, chemotherapeutic agents (cisplatin, docetaxel, AEZS-112), PI3K/AKT inhibitors (perifosine, AEZS-129), an ERK inhibitor (AEZS-134), and dual PI3K/ERK inhibitor AEZS-136 applied as single agent therapies and in combinations. MDA-MB-231 and HCC1806 TNBC cells both expressed receptors for GnRH...In MDA-MB-231 cells, synergy was observed after co-treatment with triptorelin and ERK inhibitor AEZS-134 and dual PI3K/ERK inhibitor AEZS-136.
    DOI:
    10.1007/s11523-014-0340-y